Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

被引：0
|
作者：
Rupert Bartsch
Simon Peter Gampenrieder
Gabriel Rinnerthaler
Edgar Petru
Daniel Egle
Andreas Petzer
Marija Balic
Ursula Pluschnig
Thamer Sliwa
Christian Singer
机构：
[1] Medical University of Vienna,Department of Medicine I, Division of Oncology
[2] Paracelsus Medical University Salzburg,Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center
[3] Medical University of Graz,University Hospital for Gynecology and Obstetrics, Clinical Department of Gynecology
[4] Medical University of Innsbruck,Department of Gynecology, Breast Cancer Center Tirol
[5] Ordensklinikum Linz GmbH,Barmherzige Schwestern, Elisabethinen, Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology
[6] Medical University of Graz,Department of Internal Medicine, Division of Clinical Oncology
[7] Klagenfurt Hospital,Department of Internal Medicine and Hematology and Internal Oncology
[8] Hanusch Hospital,3rd Medical Department, Hematology and Oncology
[9] Medical University of Vienna,Department of Gynecology, Breast Cancer Center Vienna
来源：
Wiener klinische Wochenschrift | 2022年 / 134卷
关键词：
HER2; Trastuzumab; Pertuzumab; Antibody-conjugate; Tyrosin-kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.
引用
收藏
页码：63 / 72
页数：9
相关论文
共 50 条
  • [1] Updated Austrian treatment algorithm in HER2+metastatic breast cancer
    Bartsch, Rupert
    Gampenrieder, Simon Peter
    Rinnerthaler, Gabriel
    Petru, Edgar
    Egle, Daniel
    Petzer, Andreas
    Balic, Marija
    Pluschnig, Ursula
    Sliwa, Thamer
    Singer, Christian
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (1-2) : 63 - 72
  • [2] Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Petru, Edgar
    Egle, Daniel
    Gnant, Michael
    Balic, Marija
    Sliwa, Thamer
    Singer, Christian
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 (11-12) : 347 - 361
  • [3] Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity
    Reactions Weekly, 2020, 1794 (1) : 12 - 12
  • [4] ECONOMIC IMPACT OF THE INCLUSION OF PERTUZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER HER2+
    Nazco, G.
    Gutierrez, F.
    Bullejos, M.
    Vina, M.
    Gonzalez, I
    Valcarcel, C.
    VALUE IN HEALTH, 2014, 17 (07) : A638 - A638
  • [5] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer
    S Menjón-Beltrán
    R Olivencia-Dueso
    E González-Jiménez
    MJ Titos
    Breast Cancer Research, 9
  • [6] Pertuzumab in the Treatment of HER2+ Breast Cancer
    Jhaveri, Komal
    Esteva, Francisco J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (04): : 591 - 598
  • [7] Real-world treatment in patients with HER2+ metastatic breast cancerTreatment decisions in HER2+ mBC
    R. Colomer
    P. Hall
    M. Szkultecka-Debek
    R. C. Bondi
    A. Flinois
    S. Auziere
    J. Y. Le Cléac’h
    Breast Cancer Research and Treatment, 2018, 168 : 197 - 205
  • [8] Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
    Moilanen, Tiina
    Mustanoja, Susanna
    Karihtala, Peeter
    Koivunen, Jussi P.
    ESMO OPEN, 2017, 2 (03)
  • [9] Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options
    Premji, Sarah K.
    O'Sullivan, Ciara C.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2024, 18
  • [10] Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
    Bruno, R
    Washington, CB
    Lu, JF
    Lieberman, G
    Banken, L
    Klein, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (04) : 361 - 369
12345